New Rochelle, NY, August 15, 2017--A new study has shown that use of intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury (TBI) was associated with a significant decrease in mortality, but it did not improve the rate of favorable outcomes. Although ICP monitoring was linked to more aggressive therapy, the researchers concluded that current therapies cannot adequately control increased ICP, as reported in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website until September 15, 2017.
Eiichi Suehiro, MD, PhD, Yuichi Fujiyama, MD, Hiroyasu Koizumi, MD, PhD, and Michiyasu Suzuki, MD, PhD, from Yamaguchi University School of Medicine, Ube, Japan and representing The Japan Neurotrauma Data Bank Committee of The Japan Society of Neurotraumatology, Tokyo, coauthored the article entitled "Directions for Use of Intracranial Pressure Monitoring in Treatment of Severe Traumatic Brain Injury Using Data from the Japan Neurotrauma Data Bank."
In a retrospective study of nearly 1,100 patients with severe TBI, the researchers reported a rate of ICP monitoring of only 28%, suggesting that use of this method has declined compared to previous studies. The patients who received ICP monitoring had significantly higher rates of therapy with hyperventilation, hyperosmolar diuretics, sedatives, anticonvulsants, and surgery, and more intensive body temperature management. Yet there was no significant difference in the favorable outcome rate between the ICP and non-ICP monitoring groups of patients.
"This well-reasoned retrospective analysis focuses on an issue that continues to generate controversy in relation to the care and management of traumatically brain injured patients," says John T. Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma and Professor, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond. "What is of note in this communication is the fact that although those patients were aggressively managed, with concomitant ICP monitoring revealing a significant reduction in mortality, this occurred without any improvement in outcome, a finding that further highlights the continued controversy surrounding routine ICP monitoring."
About the Journal
Journal of Neurotrauma is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. Journal of Neurotrauma is the official journal of the National Neurotrauma Society and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the Journal of Neurotrauma website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Therapeutic Hypothermia and Temperature Management, Brain Connectivity, and Tissue Engineering. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.